JAK Inhibitor Benefits in Type 1 Diabetes Lost After Discontinuation

MedPage Today) — The effects of the JAK inhibitor baricitinib (Olumiant) waned after treatment was stopped among patients with new-onset type 1 diabetes, 2-year data from the phase II BANDIT trial showed.
After treatment was stopped, C-peptide…